Compare · AKYA vs MTD
AKYA vs MTD
Side-by-side comparison of Akoya BioSciences Inc. (AKYA) and Mettler-Toledo International Inc. (MTD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKYA and MTD operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- MTD carries a market cap of $34.07B.
- MTD has hit the wire 26 times in the past 4 weeks while AKYA has been quiet.
- MTD has more recent analyst coverage (25 ratings vs 13 for AKYA).
- Company
- Akoya BioSciences Inc.
- Mettler-Toledo International Inc.
- Price
- -
- -
- Market cap
- -
- $34.07B
- 1M return
- -
- +5.40%
- 1Y return
- -
- +22.63%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1997
- News (4w)
- 0
- 26
- Recent ratings
- 13
- 25
Akoya BioSciences Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Latest AKYA
- SEC Form 15-12G filed by Akoya BioSciences Inc.
- SEC Form EFFECT filed by Akoya BioSciences Inc.
- Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Legal Officer Kamocsay Jennifer disposed of 179,272 shares, closing all direct ownership in the company (SEC Form 4)
- CFO Ek John Frederick disposed of 268,202 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Clinical Officer Bamford Pascal disposed of 205,738 shares, closing all direct ownership in the company (SEC Form 4)
- Director Winkler Matthew disposed of 984,513 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Shepler Robert G
Latest MTD
- President and CEO Kaltenbach Patrick was granted 534 shares, increasing direct ownership by 11% to 5,510 units (SEC Form 4)
- Head of Process Analytics Keller Gerry was granted 62 shares, increasing direct ownership by 20% to 379 units (SEC Form 4)
- Chief Financial Officer Vadala Shawn was granted 176 shares, increasing direct ownership by 3% to 5,934 units (SEC Form 4)
- Head of PI, Retail, and GSC Wittorf Oliver was granted 51 shares, increasing direct ownership by 9% to 600 units (SEC Form 4)
- Head of Asia & Pacific Wong Ann Ping Richard was granted 64 shares, increasing direct ownership by 9% to 767 units (SEC Form 4)
- Director Salice Thomas P was granted 77 shares, increasing direct ownership by 26% to 369 units (SEC Form 4)
- Director Zhang Ingrid was granted 54 shares, increasing direct ownership by 26% to 261 units (SEC Form 4)
- Director Wienand Wolfgang was granted 54 shares, increasing direct ownership by 30% to 237 units (SEC Form 4)
- Director Tokich Michael J was granted 54 shares, increasing direct ownership by 108% to 104 units (SEC Form 4)
- Director Shuman-Fabbri Natalia was granted 54 shares, increasing direct ownership by 338% to 70 units (SEC Form 4)